Associations Between Psilocybin Use Motives and Cognitive, Affective, and Behavioural Self-Stigma.
Graeme Knibb, Ruby Ward, Paul Christiansen, Carl Alexander Roberts
Substance Use & Misuse March 28, 2026 DOI: 10.1080/10826084.2026.2643418 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Cross-sectional survey Peer reviewed |
|---|---|
| Sample size | 239 |
| Population | People with prior experience of psilocybin |
| Topics | Psilocybin |
| Keywords | Motivation Psychedelics Self-stigma |
| Key findings | Greater therapeutic growth motives for psilocybin use were associated with reduced self-stigma, while greater social recreation motives were associated with increased self-stigma. |
Abstract
Background: Self-stigma refers to the internalization of negative societal beliefs and has been associated with reduced self-efficacy, self-esteem and treatment avoidance among substance users. However, little research has explored antecedents of self-stigma such as substance use motives. This may be particularly salient for psilocybin which is used both as a therapeutic agent and a recreational substance and these different motivations for use may shape how users' behaviors are interpreted and internalized.
Methods: The current study assessed associations between motives for psilocybin use and self-stigma across cognitive, affective and behavioral dimensions. Participants with prior experience of psilocybin (N = 239) completed an online questionnaire assessing their motives for using psilocybin and levels of self-stigma. A principal component analysis identified three components of psilocybin use motives, Social Recreation (ωt = 0.78), Experiential Enhancement (ωt = 0.80) and Therapeutic Growth (ωt = 0.73).
Results: Hierarchical regression analyses demonstrated that greater Therapeutic Growth motives were associated with reduced self-stigma while greater Social Recreation motives were associated with increased self-stigma for all dimensions. No significant associations were found for Experiential Enhancement. Therapeutic Growth motives were also associated with increased frequency of psilocybin use.
Conclusions: Although the variance explained was modest, these findings suggest that motives for psilocybin use may influence the extent to which users internalize stigma. This finding has implications for other substances and is important given the growing clinical interest in psilocybin.
Comparable studies
Other cross-sectional and survey studies on psilocybin, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences Individuals who had consumed psilocybin mushrooms and experienced a psychologically... | 2016 | Cross-sectional survey | n = 1,993 |
| The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms Internet survey respondents reporting challenging experiences with psilocybin | 2016 | Questionnaire development and validation | |
| Psychedelics and Mental Health: A Population Study Adult population in the United States | 2013 | Cross-sectional survey | n = 130,152 |
| Cessation and reduction in alcohol consumption and misuse after psychedelic use Individuals with prior alcohol use disorder who reported cessation or reduction in... | 2019 | Cross-sectional survey | n = 343 |
| Patterns of simultaneous polysubstance use in drug using university students Drug-using university students | 2006 | Cross-sectional survey | n = 149 |
Citations in the library
Cites 11
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder JAMA Psychiatry November 4, 2020
- Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology November 8, 2017
- Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews Expert Review of Clinical Pharmacology August 13, 2018
and 6 more in the library